BBC — Virtus LifeSci Biotech Clinical Trials ETF
Data updated: 2026-06-22
BBC — Virtus LifeSci Biotech Clinical Trials ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $37.33M AUM · 0.79% expense ratio · 132.8% 1-yr return. From SEC regulatory filings.
BBC Fund Overview
BBC — Virtus LifeSci Biotech Clinical Trials ETF is a US ETF managed by ETFis Series Trust I, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: ETFis Series Trust I
- Category: United States Health Care Equity
- Assets under management: $37.33M
- 1-year return: 132.8%
- Ticker: BBC
- SEC CIK: 0001559109
- SEC series ID: S000047353
- Share class ID: C000148681
BBC Holdings
Top 10 holdings of Virtus LifeSci Biotech Clinical Trials ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Dreyfus Government Cash Manage | 2.28% |
| Erasca, Inc. | 2.19% |
| Enliven Therapeutics, Inc. | 1.81% |
| Tango Therapeutics, Inc. | 1.71% |
| Oruka Therapeutics, Inc. | 1.68% |
| Spyre Therapeutics, Inc. | 1.64% |
| Alumis, Inc. | 1.59% |
| Dianthus Therapeutics, Inc. | 1.54% |
| Kodiak Sciences, Inc. | 1.35% |
| Revolution Medicines, Inc. | 1.35% |
BBC Portfolio Allocation
Asset-class allocation of Virtus LifeSci Biotech Clinical Trials ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 2.3% |
BBC Performance
Total returns for BBC (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 13.5% |
| 1 year | 132.8% |
| 3 years (annualised) | 25.3% |
| 5 years (annualised) | -2.3% |
BBC Risk Information
Risk metrics for BBC, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 27.0%
BBC Costs and Fees
BBC costs about $79 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.79%
- Gross expense ratio: 0.79%
- Portfolio turnover: 53%
- Brokerage commissions: 12.92 bps of average net assets (SEC N-CEN)
BBC Cashflows
Over the 12 months to 2026-04, Virtus LifeSci Biotech Clinical Trials ETF had net inflows of $5.55M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $175.24K |
| 2026-03 | −$1.97M |
| 2026-02 | −$26.30K |
| 2026-01 | $1.89M |
| 2025-12 | $5.94M |
| 2025-11 | $1.81M |
BBC Debt Constituents
No individual debt constituents are reported in Virtus LifeSci Biotech Clinical Trials ETF's latest SEC N-PORT filing.
BBC Prospectus and SEC Filings
Official Virtus LifeSci Biotech Clinical Trials ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.